Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis
C. K. Mok, Y. L. Ng, B. A. Ahidjo, R. C. H. Lee, M. W. C. Loe, J. Liu, K. S. Tan, P. Kaur, W. J. Chng, J. E. L. Wong, D. Y. Wang, E. W. Hao, X. Hao, Y. W. Tan, T. M. Mak, C. Lin, R. V. T. P. Lin, P. A. Tambyah, J. Deng, J. J. H. Chu
Abstract
COVID-19, the disease caused by SARS-CoV-2 (1), was declared a pandemic by the World Health Organization (WHO) in March 2020 (2). While awaiting a vaccine, several antivirals are being used to manage the disease with limited success (3, 4). To expand this arsenal, we screened 4 compound libraries: a United States Food and Drug Administration (FDA) approved drug library, an angiotensin converting enzyme-2 (ACE2) targeted compound library, a flavonoid compound library as well as a natural product library. Of the 121 compounds identified with activity against SARS-CoV-2, 7 were shortlisted for validation. We show for the first time that the active form of Vitamin D, calcitriol, exhibits significant potent activity against SARS-CoV-2. This finding paves the way for consideration of host-directed therapies for ring prophylaxis of contacts of SARS-CoV-2 patients.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin
K. S. Plante, J. A. Plante, … S. C. Weaver·bioRxiv·Jul 15, 2020
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
S. B. Biering, E. Van Dis, … S. A. Stanley·bioRxiv·Dec 30, 2020
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
S. Weston, C. M. Coleman, … M. Frieman·bioRxiv·Mar 25, 2020
- Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Y. Unoh, S. Uehara, … Y. Tachibana·bioRxiv·Jan 26, 2022
- Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
W. Chiu, L. Verschueren, … E. Van Damme·bioRxiv·Feb 2, 2022